Of the 16 converted IPD individuals, eight had plasma NfL and tau levels measured by simplex Simoa platforms and published previously.44 In addition to the IPD-AR cohort, plasma (n = 3; individuals = 2) and CSF (n = 5; individuals = 4) samples from asymptomatic h-GH iCJD-AR individuals were also tested against symptomatic IPD, CJD (sCJD, iCJD and vCJD), and healthy control cohorts, with baseline demographics summarized in Table 1. This evidence concerns the gene MAPT and variant Creutzfeldt-Jakob disease.